For research use only
| Cat No. | ABC-TC0044 |
| Product Type | Human Uterine Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Uterus |
| Disease | Adenocarinoma |
| Product Code | AN3_CA; AN3-CA; AN3 Ca; AN3CA; AN-3; AN3; Acanthosis Nigricans 3rd attempt-CArcinoma |
Organ: uterus Tissue: endometrium Disease: adenocarcinoma
AN3 CA cell line is a human epithelial tumor cell line established from a metastatic endometrial adenocarcinoma of uterine origin. It was derived from a lymph node metastasis of a 55-year-old female patient with poorly differentiated endometrial cancer. AN3 CA cells exhibit polygonal morphology and grow in loosely adherent clusters in vitro. The line harbors mutations in key tumor suppressors such as PTEN and exhibits microsatellite instability. Karyotype analysis reveals complex chromosomal aberrations, including abnormalities of chromosomes 1 and 10, commonly observed in uterine neoplasms. AN3 CA is tumorigenic in immunodeficient mice and widely used for modeling metastatic endometrial cancer, hormone response, and resistance to chemotherapy. The cells are tumorigenic in immunodeficient mice but non-metastatic in vivo. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | AN3_CA; AN3-CA; AN3 Ca; AN3CA; AN-3; AN3; Acanthosis Nigricans 3rd attempt-CArcinoma |
| Species | Human |
| Cat.No | ABC-TC0044 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Uterus |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Uterine Cancer Cell Lines |
AN3 CA is a widely used model for advanced endometrial adenocarcinoma, particularly for studying mechanisms of metastasis, hormone insensitivity, and therapeutic resistance. Its genetic profile makes it ideal for investigating PTEN loss, microsatellite instability, and PI3K/AKT signaling in uterine cancers. It is commonly used in drug screening platforms targeting endometrial tumors that are unresponsive to hormonal therapy. The cell line also supports research in cancer immunology, molecular diagnostics, and personalized medicine. Its consistent in vitro behavior and tumorigenicity in vivo make AN3 CA an essential system for translational studies in gynecologic oncology, helping to bridge laboratory models with clinical relevance.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
